← Back to all trials
Completed
NCT07220629
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
Conditions: Obesity
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 82
Sponsor: Rezera (formerly NodThera Limited)
Location: Investigative Site Mesa Arizona
Summary
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Eligibility Criteria
Inclusion Criteria:
1. Male or female aged 18 to 75 years (inclusive) at Screening who have signed informed consent and are willing and able to comply with the study protocol.
2. Have a BMI of ≥30.0 kg/m2 and \
Source: ClinicalTrials.gov (NCT07220629). StuddyBuddy aggregates publicly available trial information.
